Safety and Feasibility Study of Dapivirine (TMC120) Vaginal Ring in Belgium
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This Phase I trial will assess the feasibility of using a vaginal ring to deliver the candidate microbicide dapivirine (TMC120) for 7 days. The study population will consist of 13 healthy, sexually abstinent women. Safety and tolerability will be assessed through clinical and laboratory assessments. Feasibility of drug delivery will be assessed by measuring dapivirine (TMC120) concentrations in vaginal fluids, vaginal and cervical epithelial tissue, and plasma.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 50 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Female, age 18-50 years
Willing and able to provide written informed consent
HIV-uninfected and otherwise healthy
Willing to abstain from sexual activity and from use of vaginal products while participating in the study
Currently using oral contraceptives for pregnancy prevention
Willing to use oral contraceptives as needed to avoid menstruation while taking part in this study
History of allergy to TMC120 or to the constituents of the vaginal ring
History of diagnosis of and/or treatment for a sexually transmitted disease within the last three months
History of genital tract surgery within the last month
Currently pregnant or breastfeeding, or within two months of last pregnancy outcome
Currently or within one month of participating in any other clinical research study
Current vulvar or vaginal symptoms / abnormalities that could influence the study results
Current non-iatrogenic pelvic/colposcopic exam findings involving deep epithelial disruption